Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel by V. V. Breder, R. B. Alikhanov, S. S. Bagnenko, E. N. Bessonova, V. A. Isakov, N. E. Kudashkin, B. M. Medvedeva, A. V. Mishchenko, M. S. Novruzbekov, V. S.  Rudakov

“…Screening for HCC in high-risk groups (cirrhosis of any etiology, patients with chronic viral hepatitis B and patients with F3 liver fibrosis) should be organized as regular (every 6 months) liver ultrasound in combination with determination of the serum alpha-fetoprotein (AFP) level. …”
Get full text

Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database by Hideo Yasunaga, Hirotaka Chikuda, Kiyohide Fushimi, Hiromasa Horiguchi, Toru Akiyama, Kazuo Saita

“…A higher rate of in-hospital mortality was significantly associated with haemodialysis use (ORs, 10.56 (95% CI 8.12 to 13.74)), diabetes (2.37 (1.89 to 2.98)), liver cirrhosis (2.63 (1.49 to 4.63)), malignancy (2.68, (2.10 to 3.42)) and infective endocarditis (3.19 (1.80 to 5.65)).Conclusions Our study demonstrates an increasing incidence of VO, and defines risk factors for death with a nationwide database. …”
Get full text

Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease by Yunfei Wu, Yunfei Wu, Guojun Zheng, Guojun Zheng, Fan Zhang, Fan Zhang, Fan Zhang, Wenjian Li, Wenjian Li

“…Additionally, subgroup analyses were conducted to investigate the potential heterogeneity among different characteristic subgroups.ResultsThe results demonstrated a significant correlation between elevated hsCRP levels and an increased risk of significant fibrosis, advanced fibrosis, and cirrhosis in the US cohort of MASLD patients (OR 2.22, 1.69, and 2.85, respectively; all P <0.05). …”
Get full text

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic r... by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

“…The pooled SVR rate was 96.79% (95% CI: 93.37-99.13%) and 88.41% (95% CI: 82.67-93.22%) in treatment-naive and treatment-experienced patients, respectively.ConclusionSOF+VEL ± RBV, GLE+PIB, and SOF+VEL+VOX had good antiviral effectiveness for chronic HCV-GT3 infection in real-world settings. Factors such as cirrhosis and treatment experience, especially previous DAA treatment failure, may influence the SVR rate.…”
Get full text

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy by K. R. Dudina, P. A. Belyy, I. V. Maev, N. Kh. Safiullina, E. A. Klimova, S. A. Shutko, O. O. Znoyko, N.  D. Yushchuk

“…In the long-term period after reaching SVR, regression of liver fibrosis was diagnosed in 80 % of cases (including in patients with cirrhosis), and the progression of fibrosis was in 3 % of patient. …”
Get full text

The role of the interleukin family in liver fibrosis by Zixin Zhang, Zixin Zhang, Jiahui Wang, Hui Li, Qun Niu, Qun Niu, Yujing Tao, Yujing Tao, Xin Zhao, Xin Zhao, Zijian Zeng, Zijian Zeng, Haijian Dong, Haijian Dong

“…It is a critical step in the progression from chronic liver disease to cirrhosis and hepatocellular carcinoma. No chemical or biological drugs have been approved for the treatment of liver fibrosis. …”
Get full text

The clinical role of blood coagulation and platelet receptors gene allelic variants in development of cryoglobulinemic vasculitis at chronic hepatitis C by Yekaterina Ye. Starostina, M. V. Sokolova, L. M. Samokhodskaya, T. П. Rozina, T. N. Krasnova, Ye. B. Yarovaya, N. A. Mukhin

“…Original study included overall 200 patients with CHCs and liver cirrhosis in its outcome, who were divided into 3 groups: patients without cryoglobulinemia (CG, n=123), those with asymptomatic cryoglobulinemia (ACG, n=40) and with cryoglobulinemic vasculitis (CGV, n=37). …”
Get full text

Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response by T. M. Ignatova, T. N. Lopatkina, V. P. Chulanov, Ye. V. Gaydasheva, S. N. Batskikh, G. V. Mikhaylovskaya, D. T. Abdurakhmanov, S. Yu. Karpov, Ye. N. Nikulkina, O. A. Chernova

“…Overall 208 patients with CHC, including 12 at the stage of liver cirrhosis (LC), who achieved SVO were investigated. …”
Get full text

Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy by Sol Jin, So Yun Lim, Yun Woo Lee, Heungsup Sung, Mi-Na Kim, Seongman Bae, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Eun Hee Song, Yong Pil Chong

“…In multivariable analysis, independent risk factors for breakthrough BSI during tigecycline therapy were liver cirrhosis (adjusted odds ratio [aOR], 3.09), indwelling catheter (aOR, 3.42), previous Candida colonization (aOR, 14.95), and previous multi-drug resistant bacteria colonization (aOR, 10.30). …”
Get full text

Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients by Yu-Xuan Song, Guang-Jun Song, Hui Ma, Bo Feng, Yan-Di Xie

“…The cumulative incidence rates of cirrhosis and hepatocellular carcinoma at 192 weeks were 3.9% and 0.7%, respectively. …”
Get full text

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program by V. T. Ivashkin, M. V. Mayevskaya, D. T. Abdurakhmanov, I. G. Bakulin, N. I. Geyvandova, M. L. Zubkin, S. N. Kizhlo, A. V. Kuznetsova, I. B. Latysheva, N. A. Mamonova, V. G. Morozov, O. I. Sagalova, Ye. V. Esaulenko, Ye. O. Lyusina

“…The options of antiviral therapy (AVT) in the stages of severe liver fibrosis and cirrhosis (LC) as well as in the patients with comorbidities for the long time were limited to the standard therapy by pegilated interferon (peg-IFN) in combination to ribavirin (RBV). …”
Get full text

Simultaneous Liver Venous Deprivation Following Hepatic Arterial Chemoembolization Before Major Hepatectomy for Hepatocellular Carcinoma: A New Methods to Achieve Hypertrophy Liver... by Zhang S, Song R, Hou C, Yao H, Xu J, Zhou H, Li S, Cai W, Fei Y, Meng F, Yin D, Wang J, Zhang S, Liu Y, Wang J, Liu L

“…At the first assessment after TACE-LVD, most patients exhibited sufficient FLR for hepatectomy, except for 4 patients with cirrhosis. The modified response evaluation criteria for solid tumor assessment revealed a disease control rate of 95.7%, with only 1 patient (Barcelona Clinic Liver Cancer stage C) developing intrahepatic disease progression.Conclusion: TACE-LVD seems to be a feasible, safe, and effective strategy for rapid FLR hypertrophy. …”
Get full text

Diagnostic accuracy of calculated serum osmolarity to predict dehydration in older people: adding value to pathology laboratory reports by Lee Shepstone, John F Potter, Lee Hooper, Asmaa Abdelhamid, Amy Jennings, Paul R Hunter, W Garry John, Neil P Walsh, Adam Ali, Diane K Bunn, Susan Kerry, Gregor Lindner, Carmen A Pfortmueller, Fredrik Sjöstrand, Susan J Fairweather-Tait

“…Objectives To assess which osmolarity equation best predicts directly measured serum/plasma osmolality and whether its use could add value to routine blood test results through screening for dehydration in older people.Design Diagnostic accuracy study.Participants Older people (≥65 years) in 5 cohorts: Dietary Strategies for Healthy Ageing in Europe (NU-AGE, living in the community), Dehydration Recognition In our Elders (DRIE, living in residential care), Fortes (admitted to acute medical care), Sjöstrand (emergency room) or Pfortmueller cohorts (hospitalised with liver cirrhosis).Reference standard for hydration status Directly measured serum/plasma osmolality: current dehydration (serum osmolality >300 mOsm/kg), impending/current dehydration (≥295 mOsm/kg).Index tests 39 osmolarity equations calculated using serum indices from the same blood draw as directly measured osmolality.Results Across 5 cohorts 595 older people were included, of whom 19% were dehydrated (directly measured osmolality >300 mOsm/kg). …”
Get full text

Factors influencing in-hospital mortality for salvage percutaneous transjugular intrahepatic portosystemic shunting in cirrhotic patients with recalcitrant variceal bleeding after... by J E J Krige, E G Jonas, M Setshedi, S J Beningfield, U K Lotze, M M Bernon, S Burmeister, J C Kloppers

“…The causes of portal hypertension were alcohol-related (n=24) and non-alcohol-related cirrhosis. Salvage TIPS controlled bleeding in 32 patients, with recurrence in 1. …”
Get full text

Efficacy of TIPS plus extrahepatic collateral embolisation in real-world data: a validation study by Chao Chen, Feng Zhang, Hao Wu, Wei Wu, Hui Xue, Yuzheng Zhuge, Chunqing Zhang, Guangchuan Wang, Zhengjie Li, Qiong Wu, Bo Wei, Jun Tie, Xiubin Sun, Lianhui Zhao, Yifu Xia, Jiao Xu, Peijie Li

“…This study aims to confirm the effectiveness of TIPS+E using real-world data.Methods The multicentre retrospective cohort included 2077 patients with cirrhosis who underwent TIPS±E (TIPS: 631, TIPS+E: 1446) between January 2010 and December 2022. …”
Get full text

Risk of hepatocellular carcinoma in Asian patients with primary biliary cholangitis: A nationwide and hospital cohort study by Jihye Lim, Ye-Jee Kim, Sehee Kim, Jonggi Choi

“…Older age (subdistribution hazard ratio [SHR]: 1.05, 95% CI: 1.00–1.10), male sex (SHR: 3.00, 95% CI: 1.11–8.13), current alcohol consumption (SHR: 3.70, 95% CI: 1.08–12.59), and cirrhosis (SHR: 5.17, 95% CI: 2.07–12.93) were identified as risk factors in the hospital cohort. …”
Get full text

Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations by Alia Hadefi, Morgane Leprovots, Gilles Dinsart, Maryam Marefati, Marjorie Vermeersch, Daniel Monteyne, David Pérez-Morga, Anne Lefort, Frédérick Libert, Laurine Verset, Claire Liefferinckx, Christophe Moreno, Jacques Devière, Eric Trépo, Marie-Isabelle Garcia

“…Background and Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Though MASH is closely tied to metabolic risk factors, the underlying pathogenic mechanisms remain scarcely understood. …”
Get full text

Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies by Jinlin Hou, Thomas Berg, Arndt Vogel, Teerha Piratvisuth, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Katarina Malinowsky, Peter Findeisen, Johannes Kolja Hegel, Wenzel Schöning, Kairat Madin, Konstantin Kroeniger, Henry Lik-Yuen Chan, Ashish Sharma

“…The GAAD and GALAD algorithms demonstrated similar good performance regardless of disease etiology, presence of cirrhosis, geographical region, and within pan-tumor specificity panels (p <0.001). …”
Get full text

Liver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression by Alena Laschtowitz, Eric L. Lindberg, Anna-Maria Liebhoff, Laura Anne Liebig, Christian Casar, Silja Steinmann, Adrien Guillot, Jun Xu, Dorothee Schwinge, Michael Trauner, Ansgar Wilhelm Lohse, Stefan Bonn, Norbert Hübner, Christoph Schramm

“…Background &amp; Aims: Primary sclerosing cholangitis (PSC) is a chronic heterogenous cholangiopathy with unknown etiology where chronic inflammation of the bile ducts leads to multifocal biliary strictures and biliary fibrosis with consecutive cirrhosis development. We here aimed to identify a PSC-specific gene signature associated with biliary fibrosis development. …”
Get full text

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk by Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla, Víctor Sapena, Zoe Mariño, Sabela Lens, Ramón Vilana, Isabel Nuñez, Anna Darnell, Ernest Belmonte, Ángeles García-Criado, Alba Díaz, Marco Sanduzzi-Zamparelli, Carla Fuster, Sergio Muñoz-Martínez, Carmen Ayuso, Jordi Rimola, Alejandro Forner, Alexandre Soler, Ferran Torres, José Ríos, Jordi Bruix, Andrew M. Moon, Xavier Forns, María Reig

“…At the time of SVR, 65.9% had cirrhosis, median BMI was 27.1 kg/m2, 74.2% were overweight or obese and 6.6% had an US with hepatic steatosis. …”
Get full text